et al. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid ...

中位生存期为43.2个月，客观缓解率（ORR）为50%。BRAFV600E突变患者队列的生存期——43.2个月——是迄今为止发表的间变性甲状腺癌系统治疗最长的生存期。三个队列总体的中位生存期为19个月，与间变性甲状腺癌患者的5个月的历史生存期相比有改善。队列2纳入21 ...

PTC 的遗传标记是 BRAF 基因中的一个特定突变，即 BRAFV600E 突变。存在这种基因突变的患者通常需要使用威罗菲尼这种针对此类突变的药物。但是大 ...

ChristianaCare基因编辑研究所的研究人员使用CRISPR基因编辑工具禁用了一种侵袭性黑色素瘤的耐药性基因突变，仅在肿瘤细胞中恢复对抗癌药物敏感性。 黑素瘤治疗“向前迈进了一大步” 黑色素瘤仍然是最具挑战性的癌症之一，耐药性突变——主要是激活BRAF突变 ...

The longest OS among the cohorts was 43.2 months in patients with BRAFV600E mutations—the longest OS published to date for systematic therapy in ATC. "Patients with anaplastic thyroid carcinoma ...

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict ...

It’s for people who have locally advanced bowel cancer with a gene change called BRAFV600E. Read more about A trial looking at targeted cancer drugs or chemotherapy before surgery for locally advanced ...

This trial is looking at improving treatment for bowel cancer. It’s for people who have locally advanced bowel cancer with a gene change called BRAFV600E. Read more about A trial looking at targeted ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...